搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
ENDPOINTS NEWS
1 小时
Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life
Kronos Bio announces 83% workforce reduction and CEO Norbert Bischofberger's departure, with CFO Deborah Knobelman taking ...
ENDPOINTS NEWS
2 小时
Acadia snaps up an essential tremor drug after field's summer setbacks
Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...
ENDPOINTS NEWS
3 小时
Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway
Idorsia is making moves to stretch its cash reserves further. The Swiss drugmaker said it is narrowing its ...
ENDPOINTS NEWS
11 小时
To lead NIH, Trump taps Stanford academic and pandemic response critic ...
President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...
ENDPOINTS NEWS
20 小时
Axsome moves toward NDA filing for narcolepsy drug following positive ...
Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...
ENDPOINTS NEWS
22 小时
Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big ...
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...
ENDPOINTS NEWS
17 小时
The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will ...
The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular ...
ENDPOINTS NEWS
22 小时
Food allergy biotech Alladapt closes after Phase 3 talks with FDA
Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...
ENDPOINTS NEWS
23 小时
Soleno’s rare pediatric disease drug faces PDUFA delay by three months
FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...
ENDPOINTS NEWS
23 小时
Agilent reveals plans to remodel operations as annual revenue dips
Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...
ENDPOINTS NEWS
23 小时
Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor
Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈